Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Impact of Comorbidities and Prospective Functional Geriatric Assessment Tools (CF-GA) As an Aide to Understand Outcome, Therapy Tolerance, Side Effects and Clinical Trial Eligibility in Multiple Myeloma (MM) Patients (pts)

Alexander Zober, MD, Mandy Möller, Sandra-Maria Dold, Gabriele Ihorst, PhD, Stefanie Hieke, PhD, Jochen Knaus, Milena Pantic, PhD, Barbara Deschler-Baier, MD, Stefan Knop, Hermann Einsele, Christian Langer, Lars-Olof Muegge, MD, Wolfram Poenisch, MD, Justus Duyster, MD PhD, Martin Schumacher, PhD, Ralph M. Waesch, MD PhD, Monika Engelhardt, MD PhD

Blood (2015) 126 (23): 5616.

https://doi.org/10.1182/blood.V126.23.5616.5616

Published: 2015

Journal Articles

Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial

Michael Lubbert, Claudia Schmoor, Björn Rüter, Mathias Schmid, Ulrich Germing, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Rainer Claus, Barbara Deschler, Björn W. Hackanson, Konstanze Döhner, Pierre Wijermans, Hartmut Döhner

Blood (2010) 116 (21): 2185.

https://doi.org/10.1182/blood.V116.21.2185.2185

Published: 2010

Journal Articles

Development of a Frailty Score for Older Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Barbara Deschler, Gabriele Ihorst, Uwe Platzbecker, MD, Ulrich Germing, Michael Lübbert

Blood (2009) 114 (22): 1775.

https://doi.org/10.1182/blood.V114.22.1775.1775

Published: 2009

Journal Articles

Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.

Michael Lübbert, Björn H. Rüter, Mathias Schmid, Rainer Claus, Ulrich Germing, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Björn Hackanson, Barbara Deschler, Pierre W Wijermans, Claudia Schmoor, Hartmut Döhner

Blood (2009) 114 (22): 4141.

https://doi.org/10.1182/blood.V114.22.4141.4141

Published: 2009

Journal Articles

Detection of Renal Impairment (RI) as One Specific Comorbidity Factor in Multiple Myeloma (MM) Patients: Multi-Center Study in 198 Consecutive Patients

Martina Kleber, Gabriele Ihorst, Barbara Deschler, Christian Jakob, MD, Peter Liebisch, Bernd Koch, Orhan Sezer, Monika Engelhardt

Blood (2008) 112 (11): 2372.

https://doi.org/10.1182/blood.V112.11.2372.2372

Published: 2008

Journal Articles

Prognostic Impact of Clinico-Pathological Parameters on the Outcome of Multiple Myeloma Patients: A Single-Center Analysis on 143 Consecutive Patients Treated with Standard Versus Intensive Chemotherapy.

Truc Ngo, MD, Martina Kleber, MD, Barbara Deschler, MD, Gabriele Ihorst, Monika Engelhardt, MD

Blood (2006) 108 (11): 5436.

https://doi.org/10.1182/blood.V108.11.5436.5436

Published: 2006

Journal Articles

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.

Michael Lübbert, Björn Rüter, Mathias Schmid, Sabine Knipp, Ulrich Germing, Christiane Dobbelstein, Hartmut Eimermacher, Barbara Deschler, Rainer Claus, Richard Schlenk, Arnold Ganser, Hartmut Döhner, Claudia Schmoor, Hartmut Henß

Blood (2005) 106 (11): 1852.

https://doi.org/10.1182/blood.V106.11.1852.1852

Published: 2005

Journal Articles

Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses

Karl-Georg Fischer, Barbara Deschler, Michael Lübbert

Blood (2003) 101 (9): 3753–3754.

https://doi.org/10.1182/blood-2002-12-3920

Published: 2003

NARROW

Impact of Comorbidities and Prospective Functional Geriatric Assessment Tools (CF-GA) As an Aide to Understand Outcome, Therapy Tolerance, Side Effects and Clinical Trial Eligibility in Multiple Myeloma (MM) Patients (pts)

Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial

Development of a Frailty Score for Older Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.

Detection of Renal Impairment (RI) as One Specific Comorbidity Factor in Multiple Myeloma (MM) Patients: Multi-Center Study in 198 Consecutive Patients

Prognostic Impact of Clinico-Pathological Parameters on the Outcome of Multiple Myeloma Patients: A Single-Center Analysis on 143 Consecutive Patients Treated with Standard Versus Intensive Chemotherapy.

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.

Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only